A pharmaceutical composition is described. The composition comprises: (i) at least one mometasone compound selected from mometasone and mometasone furoate; (ii) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, solvates of formoterol, and solvates of pharmaceutically acceptable salts of formoterol; and (iii) a propellant component comprising 1,1-difluoroethane (R-152a).